Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
$0.05
$0.05
$0.02
$0.25
$572K2.4713,394 shsN/A
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
$0.70
+6.6%
$1.62
$3.25
$17.50
$539K1.091,859 shs808,277 shs
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
$0.01
$0.01
$1.12
$430K1.91N/AN/A
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
$0.00
$0.06
$0.00
$1.69
$166K0.57215,590 shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
0.00%0.00%0.00%0.00%0.00%
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
0.00%-5.69%-12.70%-77.27%-19.31%
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
0.00%0.00%0.00%0.00%0.00%
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
0.00%0.00%-84.21%-97.60%-99.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
N/AN/AN/AN/AN/AN/AN/AN/A
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
2.4636 of 5 stars
3.34.00.00.00.01.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
0.00
N/AN/AN/A
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
0.00
N/AN/AN/A
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
0.00
N/AN/AN/A
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
2.50
Moderate Buy$4.00133,233.33% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
$1.90M0.30N/AN/A($1.63) per share-0.03
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/A($4.55) per shareN/A
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
$10.62M0.00N/AN/A($2.00) per share0.00
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
$3.09M0.05N/AN/A$1.05 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
-$40.57MN/A0.00N/AN/AN/AN/AN/A
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
-$3.68M-$3.84N/AN/AN/AN/A-786.77%N/A
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
$48.29M$1.320.00N/AN/A498.04%N/A-76.15%N/A
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
-$97.43M-$1.33N/AN/AN/AN/AN/AN/AN/A

Latest OMGAQ, ARGSQ, BCTXF, and GLGLF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
N/A-$0.06N/A-$0.05N/A$2.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/AN/AN/AN/AN/A
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/AN/A
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
N/AN/AN/AN/AN/A
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/AN/AN/A
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/A
0.07
0.07
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
N/A
0.21
0.19
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/A
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/A
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
N/A
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
97.47%
CompanyEmployeesShares OutstandingFree FloatOptionable
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
12210.59 millionN/ANot Optionable
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
8772,000N/ANot Optionable
GLG Life Tech Corp. stock logo
GLGLF
GLG Life Tech
1238.39 millionN/ANot Optionable
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
12055.37 million50.66 millionOptionable

Recent News About These Companies

OMGAQ - Omega Therapeutics Inc Executives | Morningstar
Omega Therapeutics Inc (OMGAQ)
Omega Therapeutics Hits Chapter 11
Flagship’s Omega Thera to file for bankruptcy
Flagship-backed Omega signals it’s headed toward bankruptcy
Flagship Pioneering partners with Cambridge, UK institutions
Omega Therapeutics Reports Third Quarter 2024 Results
Omega Therapeutics price target lowered to $4 from $9 at Piper Sandler

New MarketBeat Followers Over Time

Media Sentiment Over Time

Argos Therapeutics stock logo

Argos Therapeutics OTCMKTS:ARGSQ

$0.05 0.00 (0.00%)
As of 10/10/2019

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.

BriaCell Therapeutics stock logo

BriaCell Therapeutics OTCMKTS:BCTXF

$0.70 +0.04 (+6.57%)
As of 08/22/2025

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

GLG Life Tech stock logo

GLG Life Tech OTCMKTS:GLGLF

GLG Life Tech Corporation researches for, develops, grows, refines, and produces natural sweeteners extracted from the stevia plant and monk fruit in Canada and internationally. It also offers P-Pro Plus, a pea protein product; REB M GOLD, a bioconverted Rebaudioside M and Rebaudioside D. sweetener; and natural ingredients. It serves in the food and beverage industry. The company was formerly known as GLG Life Tech Limited and changed its name to GLG Life Tech Corporation in March 2007. GLG Life Tech Corporation was incorporated in 1998 and is headquartered in Richmond, Canada.

Omega Therapeutics stock logo

Omega Therapeutics OTCMKTS:OMGAQ

$0.0030 0.00 (0.00%)
As of 08/11/2025

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.